Assignee
VISTERRA INC
US37 patents
Top patents by PatentIndex Score
US9212217B2Dec 15, 2015
Antibody molecules to dengue virus and uses thereof
VISTERRA INC14 citations92
US9096657B2Aug 4, 2015
HA binding agents
VISTERRA INC13 citations92
US8877200B2Nov 4, 2014
HA binding agents
VISTERRA INC17 citations92
US10800835B2Oct 13, 2020
HA binding agents
VISTERRA INC4 citations84
US9969794B2May 15, 2018
HA binding agents
VISTERRA INC7 citations84
US11136385B2Oct 5, 2021
Methods of treating IgA nephropathy by administering an anti-APRIL (a proliferation-inducing ligand) antibody molecule
VISTERRA INC4 citations83
US10954296B2Mar 23, 2021
Method of using anti-APRIL (a proliferation-inducing ligand) antibodies to reduce IGA
VISTERRA INC4 citations83
US10385123B2Aug 20, 2019
Antibody molecules to a proliferation-inducing ligand (APRIL)
VISTERRA INC8 citations83
US10155806B2Dec 18, 2018
Antibody molecules to dengue virus and uses thereof
VISTERRA INC4 citations83
US9365639B2Jun 14, 2016
Antibody molecules to dengue virus and uses thereof
VISTERRA INC9 citations83
US11059883B2Jul 13, 2021
Antibody molecules to dengue virus and uses thereof
VISTERRA INC2 citations72
US10981982B2Apr 20, 2021
Nucleic acid molecules encoding antibodies to a proliferation-inducing ligand (APRIL)
VISTERRA INC1 citations72
US10968270B2Apr 6, 2021
Antibody molecules to a proliferation-inducing ligand (APRIL)
VISTERRA INC3 citations72
US11912781B2Feb 27, 2024
Humanized complement 5A receptor 1 antibodies and methods of use thereof
VISTERRA INC1 citations71
US11168131B2Nov 9, 2021
Antibody molecule-drug conjugates and uses thereof
VISTERRA INC4 citations69
US10513553B2Dec 24, 2019
Compositions and methods for treating and preventing influenza
VISTERRA INC6 citations67
US11230593B2Jan 25, 2022
Compositions and methods for treating and preventing influenza
VISTERRA INC4 citations63
US12054539B2Aug 6, 2024
Antibody molecules to dengue virus and uses thereof
VISTERRA INC0 citations62
US12024552B2Jul 2, 2024
Ha binding agents
VISTERRA INC0 citations62
US12415865B2Sep 16, 2025
Antibody molecules to C5AR1 and uses thereof
VISTERRA INC0 citations61
US12187807B2Jan 7, 2025
Antibody molecules to C5AR1 and uses thereof
VISTERRA INC0 citations61
US12091451B2Sep 17, 2024
Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)
VISTERRA INC0 citations61
US11773179B2Oct 3, 2023
Antibody molecules to C5aR1 and uses thereof
VISTERRA INC0 citations61
US12338291B2Jun 24, 2025
Humanized antibody molecules to CD138 and uses thereof
VISTERRA INC0 citations60
US12264203B2Apr 1, 2025
Humanized complement 5a receptor 1 antibodies and methods of use thereof
VISTERRA INC0 citations60
US12227587B2Feb 18, 2025
Humanized complement 5A receptor 1 antibodies and methods of use thereof
VISTERRA INC0 citations60
US12297249B2May 13, 2025
Interleukin-2 agents and uses thereof
VISTERRA INC0 citations59
US12084484B2Sep 10, 2024
Interleukin-2 agents and uses thereof
VISTERRA INC0 citations59
US11945868B2Apr 2, 2024
Antibody molecules to CD138 and uses thereof
VISTERRA INC1 citations59
US11858980B2Jan 2, 2024
Engineered polypeptides and uses thereof
VISTERRA INC0 citations59
US12098178B2Sep 24, 2024
Methods of using interleukin-2 agents
VISTERRA INC0 citations54
US11820979B2Nov 21, 2023
Binding polypeptides and methods of making the same
VISTERRA INC0 citations51
US11890319B2Feb 6, 2024
Antibody molecule-drug conjugates and uses thereof
VISTERRA INC0 citations49
US11969476B2Apr 30, 2024
Antibody molecule-drug conjugates and uses thereof
VISTERRA INC0 citations46
US9447133B2Sep 20, 2016
Synthetic oligosaccharides for moraxella vaccine
VISTERRA INC0 citations44
US12202885B2Jan 21, 2025
Formulations of antibody molecules to influenza virus
VISTERRA INC0 citations41
US11918651B2Mar 5, 2024
Formulations of antibody molecules to dengue virus
VISTERRA INC0 citations38